Epidemiological and Clinical Features of Critical and Non-Critical Elderly COVID-19 Patients in Udayana University Academic Hospital: A Retrospective Study
Downloads
Elderly COVID-19 patients have been associated with worse outcomes and have been presented with the highest mortality rate. However, studies on the clinical features and the differences between critical and non-critical elderly COVID-19 patients in Indonesia and even other countries are still lacking and rare. In this retrospective study, the epidemiological and clinical features of critical and non-critical elderly COVID-19 patients admitted to Udayana University Academic Hospital between April 2020 and March 2021 were analyzed and then compared. Of the 280 medical records analyzed, 60.7% were male and the median age was 65.0 years old. Based on the medical records, 18.2% of elderly patients met our criteria of critical patients. The most common symptoms presented in both category upon admission included fever and coughing. The most common comorbidity found in critical patients was heart disease and hypertension in non-critical patients. Laboratory results differences included leukocytes, neutrophils, lymphocytes, Neutrophil-to-Lymphocyte Ratio, platelets, SGOT, SGPT, and urea. Only 9.9% of critical patients and 6.1% of non-critical patients were given antiviral therapy. In contrast, 68.6% of critical patients and 76% of non-critical patients were given antibiotics. The mortality rate in critical patients was 70.6% and 0.4% in non-critical patients. Based on the results, a multimodal approach in the treatment of elderly COVID-19 patients is very essential. The higher mortality rate in elderly patients should be able to be reduced by giving early and timely antiviral therapy with the addition of effective choice of drugs.
WHO. WHO Director-General's opening remarks at the Mission briefing on COVID-19 - 12 March 2020 [Internet]. World Health Organization. 2020 [cited 2022 Jul 16]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---12-march-2020
Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. J Infect Dev Ctries. 2021;15(5):646–52.
Perrotta F, Corbi G, Mazzeo G, Boccia M, Aronne L, D'Agnano V, et al. COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clin Exp Res [Internet]. 2020;32(8):1599–608. Available from: https://doi.org/10.1007/s40520-020-01631-y
Alterovitz SSR, Mendelsohn GA. Relationship goals of middle-aged , young-old , and old-old internet daters : An analysis of online personal ads. J Aging Stud [Internet]. 2013;27(2):159–65. Available from: http://dx.doi.org/10.1016/j.jaging.2012.12.006
Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital. Acta Med Indones. 2020;52(3):199–205.
Guo T, Shen Q, Guo W, He W, Li J, Zhang Y, et al. Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province, China: A Multicenter, Retrospective Study. Gerontology. 2020;66(5):467–75.
Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect [Internet]. 2020;80(6):e14–8. Available from: https://doi.org/10.1016/j.jinf.2020.03.005
Pericí s JM, Hernandez-Meneses M, Sheahan TP, Quintana E, Ambrosioni J, Sandoval E, et al. COVID-19: From epidemiology to treatment. Eur Heart J. 2020;41(22):2092–108.
Soni SL, Kajal K, Yaddanapudi LN, Malhotra P, Puri GD, Bhalla A, et al. Demographic & clinical profile of patients with COVID-19 at a tertiary care hospital in north India. Indian J Med Res [Internet]. 2021;115–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23144490
Ismail K, Bensasi H, Taha A, Nazir A, Abdelkhalek M, Mohamed W, et al. Characteristics and outcome of critically ill patients with coronavirus disease-2019 (COVID-19) pneumonia admitted to a tertiary care center in the United Arab Emirates during the first wave of the SARS-CoV-2 pandemic. A retrospective analysis. PLoS One [Internet]. 2021;16(10 October):5–17. Available from: http://dx.doi.org/10.1371/journal.pone.0251687
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol [Internet]. 2020;20(6):363–74. Available from: http://dx.doi.org/10.1038/s41577-020-0311-8
Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol. 2022;23(1):3–20.
Pozzilli P, Lenzi A. Commentary : Testosterone , a key hormone in the context of COVID-19 pandemic. 2020;(January):19–21.
Fauzar F, Kurniati R, Abdullah F, Kam A. The Profile of COVID-19 Patients in Semen Padang Hospital Indonesia. J Kesehat Andalas. 2021;10(1):45.
AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease Insights From Cardiovascular Aging Science. JAMA Cardiol. 2020;5(7):747–8.
Faustine I, Malik A, Andrajati R, Wanandi SI. Clinical Characteristics and Severity Profile of COVID-19 Patient with Hypertension in Palu, Central Sulawesi. Indones J Pharm. 2021;32(4):563–72.
Zakhama L, Yahia F, Ben Abdelaziz A, Maghrebin PRP R, Faten Yahia C. COVID-19 and Cardiovascular diseases. Scoping review study. Tunis Med [Internet]. 2020;98(04):283–94. Available from: https://www.researchgate.net/publication/341355098
Zhang HJ, Qi GQ, Gu X, Zhang XY, Fang YF, Jiang H, et al. Lymphocyte blood levels that remain low can predict the death of patients with COVID-19. Med (United States). 2021;100(28).
Li X, Liu C, Mao Z, Xiao M, Wang L, Qi S, et al. Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care [Internet]. 2020;24(1):1–10. Available from: https://doi.org/10.1186/s13054-020-03374-8
Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. Pathobiology. 2021;88(1):15–27.
Moon AM, Barritt AS. Elevated Liver Enzymes in Patients with COVID-19: Look, but Not Too Hard. Dig Dis Sci [Internet]. 2021;66(6):1767–9. Available from: https://doi.org/10.1007/s10620-020-06585-9
Xu W, Huang C, Fei L, Li Q, Chen L. Dynamic changes in liver function tests and their correlation with illness severity and mortality in patients with covid-19: A retrospective cohort study. Clin Interv Aging. 2021;16:675–85.
Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73(5):1231–40.
Liu YF, Zhang Z, Pan XL, Xing GL, Zhang Y, Liu ZS, et al. The chronic kidney disease and acute kidney injury involvement in COVID-19 pandemic: A systematic review and meta-analysis. PLoS One [Internet]. 2021;16(1 January):1–13. Available from: http://dx.doi.org/10.1371/journal.pone.0244779
Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020;288(1):128–38.
Sun TY, Sun L, Wang RM, Ren XP, Sui DJ, Pu C, et al. Clinical efficacy and safety of moxifoxacin versus levofoxacin plus metronidazole for community-acquired pneumonia with aspiration factors. Chin Med J (Engl). 2014;127(7):1201–5.
Copyright (c) 2023 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
